CEL-SCI Corporation | WebDisclosure

Basculer en Français

8295	Companies
114810	Keywords
55260	Articles
62423	Press releases

Home
Companies
CEL-SCI Corporation

BRIEF

published on 09/04/2024 at 12:36, 2 months 16 days ago

First Berlin Equity Research Reiterates Buy Rating for CEL-SCI Corporation

Financial Results FDA Approval Multikine First Berlin Equity CEL-SCI
BRIEF

published on 09/04/2024 at 12:36, 2 months 16 days ago

First Berlin Equity Research réitère sa note d'achat pour CEL-SCI Corporation

Résultats Financiers Multikine Approbation De La FDA Première Action De Berlin CEL-SCI
PRESS RELEASE

published on 09/04/2024 at 12:31, 2 months 16 days ago

Original-Research: CEL-SCI Corporation (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research updates recommendation on CEL-SCI Corp. Analyst reiterates Buy rating and USD 6.20 target price. Positive results from financials and bias analysis

First Berlin Equity Research BUY Rating CEL-SCI Corporation USD 6.20 Target Price Bias Analysis
BRIEF

published on 06/11/2024 at 10:41, 5 months 9 days ago

First Berlin Equity Research Reaffirms Buy Recommendation for CEL-SCI Corporation

FDA Approval Clinical Study CEL-SCI Corporation Multikine Equity Research
BRIEF

published on 06/11/2024 at 10:41, 5 months 9 days ago

First Berlin Equity Research réaffirme sa recommandation d'achat pour CEL-SCI Corporation

Multikine Approbation De La FDA Étude Clinique Recherche Sur Les Actions Société CEL-SCI
PRESS RELEASE

published on 06/11/2024 at 10:36, 5 months 9 days ago

Original-Research: CEL-SCI Corporation (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research reaffirms Buy rating for CEL-SCI Corporation after FDA's positive outcome on Multikine's type B meeting, adjusting price target to USD 6.20

FDA First Berlin Equity Research Stock Market CEL-SCI Corporation Multikine
PRESS RELEASE

published on 02/14/2024 at 15:51, 9 months 6 days ago

Original-Research: CEL-SCI Corporation (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research reaffirms BUY rating for CEL-SCI Corporation (ISIN: US1508376076) with USD 8.40 price target. Completion of US manufacturing facility for lead drug Multikine expected in H1 2024

First Berlin Equity Research CEL-SCI Corporation Multikine US Manufacturing Facility USD 8.40 Price Target

Accesswire

Published on 11/21/2024 at 09:00, 58 minutes ago

ProScore Announces Domestic Content Solution for Inflation Reduction Act Requirements
Published on 11/21/2024 at 00:35, 9 hours 23 minutes ago

Vision Marine Technologies Establishes a Strategic Hub for Electric Boat Sales, Rentals, and Distribution, Marking a Milestone at Dania Pointe’s Grand Opening of Aileron Residences
Published on 11/21/2024 at 00:25, 9 hours 33 minutes ago

Biomind Labs Welcomes U.S. Policy Shift as a Historic Milestone for Psychedelic Therapies
Published on 11/21/2024 at 00:00, 9 hours 58 minutes ago

Swiss Mining Institute Conference Presentation
Published on 11/20/2024 at 23:00, 10 hours 58 minutes ago

Rektron Group Inc. Announces Appointment of a New Director and Provides Corporate Updates

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 09:41, 17 minutes ago

Original-Research: 2G Energy AG (von First Berlin Equity Research GmbH): Buy
Published on 11/21/2024 at 09:01, 57 minutes ago

Original-Research: Netfonds AG (von NuWays AG): Buy
Published on 11/21/2024 at 08:59, 58 minutes ago

Black Friday Savings: Kling AI Offers 50% Off and Free Feature Upgrades
Published on 11/21/2024 at 08:59, 58 minutes ago

Économies Black Friday : Kling AI propose 50 % de réduction et des mises à niveau gratuites des fonctionnalités
Published on 11/21/2024 at 08:15, 1 hour 43 minutes ago

EBIT increases to EUR 55.6 million. Equity (net asset value) increases by EUR 49.3 million to EUR 300.3 million, which corresponds to 70.14 euros per share. The equity ratio rises to 94.85%.

Les Echos

Published on 11/21/2024 at 06:58, 3 hours ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 3 hours ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 3 hours ago

Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Published on 11/20/2024 at 20:07, 13 hours 51 minutes ago

Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Published on 11/20/2024 at 19:20, 14 hours 38 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting

View all LES ECHOS COMFI WIRE